DV
Dividend Vision

BCYC — Bicycle Therapeutics Ltd

Bicycle Therapeutics Ltd (BCYC)

Total return is -67.5% over the past 7.2 years, 273.7 points behind SPY at 206.2%. Its deepest 1-year drawdown was 56.5%.

**Note:** The data provided appears to be for an individual stock (Bicycle Therapeutics Ltd) rather than an ETF. BCYC is a publicly traded biopharmaceutical company focused on drug development, not a diversified exchange-traded fund. As a single-stock holding, it does not have a distribution rate or meaningful expense ratio, and it does not distribute dividends. This security is suitable only for investors seeking equity exposure to a specific biotech company, not for those pursuing a dividend income strategy.

BCYC key facts

Asset type
Stock
Asset class
Equity
Inception date
05/23/2019
Last close
$3.90
Market cap
$293,905,248
Average volume
468000.0
Beta
1.55
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.15